Michael C Haffner1,2,3,4, Akshay Bhamidipati4, Harrison K Tsai4,5, David M Esopi4, Ajay M Vaghasia4, Jin-Yih Low1, Radhika A Patel1, Gunes Guner3,6, Minh-Tam Pham4, Nicole Castagna4, Jessica Hicks2, Nicolas Wyhs4, Ruedi Aebersold7,8, Angelo M De Marzo3,4,9, William G Nelson3,4,9, Tiannan Guo7,10, Srinivasan Yegnasubramanian3,4. 1. Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 2. Department of Pathology, University of Washington, Seattle, Washington, USA. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. 6. Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey. 7. Department of Biology, Institute of Molecular Systems Biology, ETH, Zürich, Switzerland. 8. Faculty of Science, University of Zürich, Zürich, Switzerland. 9. Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 10. Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang Province, China.
Abstract
BACKGROUND: Resistance to androgen deprivation therapies is a major driver of mortality in advanced prostate cancer. Therefore, there is a need to develop new preclinical models that allow the investigation of resistance mechanisms and the assessment of drugs for the treatment of castration-resistant prostate cancer. METHODS: We generated two novel cell line models (LAPC4-CR and VCaP-CR) which were derived by passaging LAPC4 and VCaP cells in vivo and in vitro under castrate conditions. We performed detailed transcriptomic (RNA-seq) and proteomic analyses (SWATH-MS) to delineate expression differences between castration-sensitive and castration-resistant cell lines. Furthermore, we characterized the in vivo and in vitro growth characteristics of these novel cell line models. RESULTS: The two cell line derivatives LAPC4-CR and VCaP-CR showed castration-resistant growth in vitro and in vivo which was only minimally inhibited by AR antagonists, enzalutamide, and bicalutamide. High-dose androgen treatment resulted in significant growth arrest of VCaP-CR but not in LAPC4-CR cells. Both cell lines maintained AR expression, but exhibited distinct expression changes on the mRNA and protein level. Integrated analyses including data from LNCaP and the previously described castration-resistant LNCaP-abl cells revealed an expression signature of castration resistance. CONCLUSIONS: The two novel cell line models LAPC4-CR and VCaP-CR and their comprehensive characterization on the RNA and protein level represent important resources to study the molecular mechanisms of castration resistance.
BACKGROUND: Resistance to androgen deprivation therapies is a major driver of mortality in advanced prostate cancer. Therefore, there is a need to develop new preclinical models that allow the investigation of resistance mechanisms and the assessment of drugs for the treatment of castration-resistant prostate cancer. METHODS: We generated two novel cell line models (LAPC4-CR and VCaP-CR) which were derived by passaging LAPC4 and VCaP cells in vivo and in vitro under castrate conditions. We performed detailed transcriptomic (RNA-seq) and proteomic analyses (SWATH-MS) to delineate expression differences between castration-sensitive and castration-resistant cell lines. Furthermore, we characterized the in vivo and in vitro growth characteristics of these novel cell line models. RESULTS: The two cell line derivatives LAPC4-CR and VCaP-CR showed castration-resistant growth in vitro and in vivo which was only minimally inhibited by AR antagonists, enzalutamide, and bicalutamide. High-dose androgen treatment resulted in significant growth arrest of VCaP-CR but not in LAPC4-CR cells. Both cell lines maintained AR expression, but exhibited distinct expression changes on the mRNA and protein level. Integrated analyses including data from LNCaP and the previously described castration-resistant LNCaP-abl cells revealed an expression signature of castration resistance. CONCLUSIONS: The two novel cell line models LAPC4-CR and VCaP-CR and their comprehensive characterization on the RNA and protein level represent important resources to study the molecular mechanisms of castration resistance.
Authors: J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg Journal: Prog Clin Biol Res Date: 1980
Authors: Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson Journal: J Clin Invest Date: 2019-07-16 Impact factor: 14.808
Authors: Michael C Haffner; Andreas Jurgeit; Chiara Berlato; Stephan Geley; Nirmala Parajuli; Akihiko Yoshimura; Wolfgang Doppler Journal: J Biol Chem Date: 2008-06-04 Impact factor: 5.157
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Nallasivam Palanisamy; Jun Yang; Peter D A Shepherd; Elsa M Li-Ning-Tapia; Estefania Labanca; Ganiraju C Manyam; Murali K Ravoori; Vikas Kundra; John C Araujo; Eleni Efstathiou; Louis L Pisters; Xinhai Wan; Xuemei Wang; Elba S Vazquez; Ana M Aparicio; Shannon L Carskadon; Scott A Tomlins; Lakshmi P Kunju; Arul M Chinnaiyan; Bradley M Broom; Christopher J Logothetis; Patricia Troncoso; Nora M Navone Journal: Clin Cancer Res Date: 2020-06-23 Impact factor: 12.531
Authors: Holly M Nguyen; Robert L Vessella; Colm Morrissey; Lisha G Brown; Ilsa M Coleman; Celestia S Higano; Elahe A Mostaghel; Xiaotun Zhang; Lawrence D True; Hung-Ming Lam; Martine Roudier; Paul H Lange; Peter S Nelson; Eva Corey Journal: Prostate Date: 2017-02-03 Impact factor: 4.104
Authors: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers Journal: Cancer Cell Date: 2011-05-17 Impact factor: 31.743
Authors: Minh-Tam Pham; Anuj Gupta; Harshath Gupta; Ajay Vaghasia; Alyza Skaist; McKinzie A Garrison; Jonathan B Coulter; Michael C Haffner; S Lilly Zheng; Jianfeng Xu; Christina DeStefano Shields; William B Isaacs; Sarah J Wheelan; William G Nelson; Srinivasan Yegnasubramanian Journal: Mol Cancer Res Date: 2022-07-06 Impact factor: 6.333